ID   ALDOB_HUMAN             Reviewed;         364 AA.
AC   P05062; Q13741; Q13742; Q5T7D6;
DT   13-AUG-1987, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 2.
DT   10-MAY-2017, entry version 193.
DE   RecName: Full=Fructose-bisphosphate aldolase B;
DE            EC=4.1.2.13;
DE   AltName: Full=Liver-type aldolase;
GN   Name=ALDOB; Synonyms=ALDB;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=6548561; DOI=10.1093/nar/12.19.7401;
RA   Paolella G., Santamaria R., Izzo P., Costanzo P., Salvatore F.;
RT   "Isolation and nucleotide sequence of a full-length cDNA coding for
RT   aldolase B from human liver.";
RL   Nucleic Acids Res. 12:7401-7410(1984).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=2410860; DOI=10.1093/nar/13.14.5055;
RA   Sakakibara M., Mukai T., Yatsuki H., Hori K.;
RT   "Human aldolase isozyme gene: the structure of multispecies aldolase B
RT   mRNAs.";
RL   Nucleic Acids Res. 13:5055-5069(1985).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA].
RX   PubMed=6585824; DOI=10.1073/pnas.81.9.2738;
RA   Rottmann W.H., Tolan D.R., Penhoet E.E.;
RT   "Complete amino acid sequence for human aldolase B derived from cDNA
RT   and genomic clones.";
RL   Proc. Natl. Acad. Sci. U.S.A. 81:2738-2742(1984).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2830249; DOI=10.1093/oxfordjournals.jbchem.a122142;
RA   Mukai T., Yatsuki H., Arai Y., Joh K., Matsuhashi S., Hori K.;
RT   "Human aldolase B gene: characterization of the genomic aldolase B
RT   gene and analysis of sequences required for multiple
RT   polyadenylations.";
RL   J. Biochem. 102:1043-1051(1987).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=3016456;
RA   Tolan D.R., Penhoet E.E.;
RT   "Characterization of the human aldolase B gene.";
RL   Mol. Biol. Med. 3:245-264(1986).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E.,
RA   Howe K.L., Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Ashwell R.I.S.,
RA   Babbage A.K., Babbage S., Bagguley C.L., Bailey J., Banerjee R.,
RA   Barker D.J., Barlow K.F., Bates K., Beasley H., Beasley O., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burford D., Burrill W.,
RA   Burton J., Carder C., Carter N.P., Chapman J.C., Chen Y., Clarke G.,
RA   Clark S.Y., Clee C.M., Clegg S., Collier R.E., Corby N., Crosier M.,
RA   Cummings A.T., Davies J., Dhami P., Dunn M., Dutta I., Dyer L.W.,
RA   Earthrowl M.E., Faulkner L., Fleming C.J., Frankish A.,
RA   Frankland J.A., French L., Fricker D.G., Garner P., Garnett J.,
RA   Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M.,
RA   Lovell J., Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S.,
RA   McLay K.E., McMurray A., Milne S., Nickerson T., Nisbett J.,
RA   Nordsiek G., Pearce A.V., Peck A.I., Porter K.M., Pandian R.,
RA   Pelan S., Phillimore B., Povey S., Ramsey Y., Rand V., Scharfe M.,
RA   Sehra H.K., Shownkeen R., Sims S.K., Skuce C.D., Smith M.,
RA   Steward C.A., Swarbreck D., Sycamore N., Tester J., Thorpe A.,
RA   Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Williams S.A., Wilming L., Wray P.W.,
RA   Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S.,
RA   Rogers J., Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   PROTEIN SEQUENCE OF 2-33 AND 357-364.
RX   PubMed=2649152; DOI=10.1016/0167-4781(89)90156-5;
RA   Sakakibara M., Takahashi I., Takasaki Y., Mukai T., Hori K.;
RT   "Construction and expression of human aldolase A and B expression
RT   plasmids in Escherichia coli host.";
RL   Biochim. Biophys. Acta 1007:334-342(1989).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 238-364.
RX   PubMed=6689266; DOI=10.1016/0006-291X(83)91243-3;
RA   Besmond C., Dreyfus J.-C., Gregori C., Frain M., Zakin M.M.,
RA   Sala Trepat J., Kahn A.;
RT   "Nucleotide sequence of a cDNA clone for human aldolase B.";
RL   Biochem. Biophys. Res. Commun. 117:601-609(1983).
RN   [10]
RP   INTERACTION WITH BBS1; BBS2; BBS4 AND BBS7, AND SUBCELLULAR LOCATION.
RX   PubMed=18000879; DOI=10.1002/cm.20250;
RA   Oeffner F., Moch C., Neundorf A., Hofmann J., Koch M., Grzeschik K.H.;
RT   "Novel interaction partners of Bardet-Biedl syndrome proteins.";
RL   Cell Motil. Cytoskeleton 65:143-155(2008).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-36; THR-39; SER-89;
RP   THR-119; SER-132; SER-272; SER-276 AND SER-309, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS).
RX   PubMed=11679716; DOI=10.1107/S0907444901012719;
RA   Dalby A.R., Tolan D.R., Littlechild J.A.;
RT   "The structure of human liver fructose-1,6-bisphosphate aldolase.";
RL   Acta Crystallogr. D 57:1526-1533(2001).
RN   [13]
RP   REVIEW ON VARIANTS.
RX   PubMed=8535439; DOI=10.1002/humu.1380060303;
RA   Tolan D.R.;
RT   "Molecular basis of hereditary fructose intolerance: mutations and
RT   polymorphisms in the human aldolase B gene.";
RL   Hum. Mutat. 6:210-218(1995).
RN   [14]
RP   VARIANT HFI PRO-150.
RX   PubMed=3383242; DOI=10.1016/S0092-8674(88)90349-2;
RA   Cross N.C.P., Tolan D.R., Cox T.M.;
RT   "Catalytic deficiency of human aldolase B in hereditary fructose
RT   intolerance caused by a common missense mutation.";
RL   Cell 53:881-885(1988).
RN   [15]
RP   VARIANT HFI ASP-175.
RX   PubMed=1967768; DOI=10.1016/0140-6736(90)90603-3;
RA   Cross N.C.P., de Franchis R., Sebastio G., Dazzo C., Tolan D.R.,
RA   Gregori C., Odievre M., Vidailhet M., Romano V., Mascali G.,
RA   Romano C., Musumeci S., Steinmann B., Gitzelmann R., Cox T.M.;
RT   "Molecular analysis of aldolase B genes in hereditary fructose
RT   intolerance.";
RL   Lancet 335:306-309(1990).
RN   [16]
RP   VARIANT HFI ARG-135.
RX   PubMed=8299883;
RA   Brooks C.C., Tolan D.R.;
RT   "A partially active mutant aldolase B from a patient with hereditary
RT   fructose intolerance.";
RL   FASEB J. 8:107-113(1994).
RN   [17]
RP   VARIANT ARG-148.
RX   PubMed=7717389;
RA   Ali M., Cox T.M.;
RT   "Diverse mutations in the aldolase B gene that underlie the prevalence
RT   of hereditary fructose intolerance.";
RL   Am. J. Hum. Genet. 56:1002-1005(1995).
RN   [18]
RP   VARIANT HFI PRO-257.
RX   PubMed=8162030; DOI=10.1093/hmg/3.1.203;
RA   Ali M., Sebastio G., Cox T.M.;
RT   "Identification of a novel mutation (Leu 256-->Pro) in the human
RT   aldolase B gene associated with hereditary fructose intolerance.";
RL   Hum. Mol. Genet. 3:203-204(1994).
RN   [19]
RP   VARIANT HFI LYS-335.
RX   PubMed=2336380; DOI=10.1093/nar/18.7.1925;
RA   Cross N.C.P., Stojanov L.M., Cox T.M.;
RT   "A new aldolase B variant, N334K, is a common cause of hereditary
RT   fructose intolerance in Yugoslavia.";
RL   Nucleic Acids Res. 18:1925-1925(1990).
RN   [20]
RP   VARIANTS HFI PRO-150; ASP-175; PRO-257; TRP-304; LYS-335 AND VAL-338.
RX   PubMed=10024431; DOI=10.1006/mcpr.1998.0208;
RA   Lau J., Tolan D.R.;
RT   "Screening for hereditary fructose intolerance mutations by reverse
RT   dot-blot.";
RL   Mol. Cell. Probes 13:35-40(1999).
RN   [21]
RP   VARIANTS HFI GLN-304 AND TRP-304, CHARACTERIZATION OF VARIANTS HFI
RP   GLN-304 AND TRP-304, AND KINETIC PARAMETERS.
RX   PubMed=10970798; DOI=10.1042/bj3500823;
RA   Santamaria R., Esposito G., Vitagliano L., Race V., Paglionico I.,
RA   Zancan L., Zagari A., Salvatore F.;
RT   "Functional and molecular modelling studies of two hereditary fructose
RT   intolerance-causing mutations at arginine 303 in human liver
RT   aldolase.";
RL   Biochem. J. 350:823-828(2000).
RN   [22]
RP   VARIANTS HFI PRO-150; ASP-175; ARG-185 AND LYS-335.
RX   PubMed=12205126; DOI=10.1136/jmg.39.9.e56;
RA   Sanchez-Gutierrez J.C., Benlloch T., Leal M.A., Samper B.,
RA   Garcia-Ripoll I., Feliu J.E.;
RT   "Molecular analysis of the aldolase B gene in patients with hereditary
RT   fructose intolerance from Spain.";
RL   J. Med. Genet. 39:E56-E56(2002).
RN   [23]
RP   VARIANTS HFI THR-74; 120-ASN-LYS-121 DEL; PRO-150; ASP-175; PHE-222;
RP   PRO-229; PRO-257; LYS-335 AND VAL-338, AND CHARACTERIZATION OF
RP   VARIANTS HFI THR-74; PHE-222 AND PRO-229.
RX   PubMed=15532022; DOI=10.1002/humu.9290;
RA   Esposito G., Santamaria R., Vitagliano L., Ieno L., Viola A.,
RA   Fiori L., Parenti G., Zancan L., Zagari A., Salvatore F.;
RT   "Six novel alleles identified in Italian hereditary fructose
RT   intolerance patients enlarge the mutation spectrum of the aldolase B
RT   gene.";
RL   Hum. Mutat. 24:534-534(2004).
RN   [24]
RP   VARIANTS HFI PRO-150; ASP-175; ARG-178; PRO-284 AND LYS-335.
RX   PubMed=15880727; DOI=10.1002/humu.9343;
RA   Santer R., Rischewski J., von Weihe M., Niederhaus M.,
RA   Schneppenheim S., Baerlocher K., Kohlschuetter A., Muntau A.,
RA   Posselt H.-G., Steinmann B., Schneppenheim R.;
RT   "The spectrum of aldolase B (ALDOB) mutations and the prevalence of
RT   hereditary fructose intolerance in Central Europe.";
RL   Hum. Mutat. 25:594-594(2005).
RN   [25]
RP   VARIANTS HFI TRP-46; PRO-150; ASP-175 AND HIS-343, AND
RP   CHARACTERIZATION OF VARIANT HFI TRP-46.
RX   PubMed=20848650; DOI=10.1002/humu.21359;
RA   Esposito G., Imperato M.R., Ieno L., Sorvillo R., Benigno V.,
RA   Parenti G., Parini R., Vitagliano L., Zagari A., Salvatore F.;
RT   "Hereditary fructose intolerance: functional study of two novel ALDOB
RT   natural variants and characterization of a partial gene deletion.";
RL   Hum. Mutat. 31:1294-1303(2010).
CC   -!- CATALYTIC ACTIVITY: D-fructose 1,6-bisphosphate = glycerone
CC       phosphate + D-glyceraldehyde 3-phosphate.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=1.6 uM for fructose 1,6-bisphosphate
CC         {ECO:0000269|PubMed:10970798};
CC         KM=2.3 mM for fructose 1-phosphate
CC         {ECO:0000269|PubMed:10970798};
CC   -!- PATHWAY: Carbohydrate degradation; glycolysis; D-glyceraldehyde 3-
CC       phosphate and glycerone phosphate from D-glucose: step 4/4.
CC   -!- SUBUNIT: Homotetramer. Interacts with BBS1, BBS2, BBS4 and BBS7.
CC       {ECO:0000269|PubMed:18000879}.
CC   -!- INTERACTION:
CC       Q8NFJ9:BBS1; NbExp=4; IntAct=EBI-1045507, EBI-1805484;
CC       Q9BXC9:BBS2; NbExp=4; IntAct=EBI-1045507, EBI-748297;
CC       Q96RK4:BBS4; NbExp=4; IntAct=EBI-1045507, EBI-1805814;
CC       Q8IWZ6:BBS7; NbExp=4; IntAct=EBI-1045507, EBI-1806001;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton, microtubule
CC       organizing center, centrosome, centriolar satellite
CC       {ECO:0000269|PubMed:18000879}.
CC   -!- DISEASE: Hereditary fructose intolerance (HFI) [MIM:229600]:
CC       Autosomal recessive disease that results in an inability to
CC       metabolize fructose and related sugars. Complete exclusion of
CC       fructose results in dramatic recovery; however, if not treated
CC       properly, HFI subjects suffer episodes of hypoglycemia, general
CC       ill condition, and risk of death the remainder of life.
CC       {ECO:0000269|PubMed:10024431, ECO:0000269|PubMed:10970798,
CC       ECO:0000269|PubMed:12205126, ECO:0000269|PubMed:15532022,
CC       ECO:0000269|PubMed:15880727, ECO:0000269|PubMed:1967768,
CC       ECO:0000269|PubMed:20848650, ECO:0000269|PubMed:2336380,
CC       ECO:0000269|PubMed:3383242, ECO:0000269|PubMed:8162030,
CC       ECO:0000269|PubMed:8299883}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: In vertebrates, 3 forms of this ubiquitous
CC       glycolytic enzyme are found, aldolase A in muscle, aldolase B in
CC       liver and aldolase C in brain.
CC   -!- SIMILARITY: Belongs to the class I fructose-bisphosphate aldolase
CC       family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/ALDOBID44287ch9q31.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X02747; CAA26526.1; -; mRNA.
DR   EMBL; D00183; BAA00125.1; -; Genomic_DNA.
DR   EMBL; M15656; AAA51691.1; -; Genomic_DNA.
DR   EMBL; M15657; AAA51691.1; JOINED; Genomic_DNA.
DR   EMBL; AL353621; CAI14614.1; -; Genomic_DNA.
DR   EMBL; CH471105; EAW58951.1; -; Genomic_DNA.
DR   EMBL; X00270; CAA25072.1; -; mRNA.
DR   EMBL; X01098; CAA25572.1; -; mRNA.
DR   CCDS; CCDS6756.1; -.
DR   PIR; A41505; ADHUB.
DR   RefSeq; NP_000026.2; NM_000035.3.
DR   UniGene; Hs.530274; -.
DR   PDB; 1QO5; X-ray; 2.50 A; A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P/Q/R=2-364.
DR   PDB; 1XDL; X-ray; 3.00 A; A/B/C/D/W/X/Y/Z=2-364.
DR   PDB; 1XDM; X-ray; 3.00 A; A/B/C/D/W/X/Y/Z=2-364.
DR   PDBsum; 1QO5; -.
DR   PDBsum; 1XDL; -.
DR   PDBsum; 1XDM; -.
DR   ProteinModelPortal; P05062; -.
DR   SMR; P05062; -.
DR   BioGrid; 106730; 13.
DR   IntAct; P05062; 28.
DR   STRING; 9606.ENSP00000363988; -.
DR   DrugBank; DB02515; 3-Phosphoglycerol.
DR   iPTMnet; P05062; -.
DR   PhosphoSitePlus; P05062; -.
DR   BioMuta; ALDOB; -.
DR   DMDM; 113611; -.
DR   EPD; P05062; -.
DR   MaxQB; P05062; -.
DR   PaxDb; P05062; -.
DR   PeptideAtlas; P05062; -.
DR   PRIDE; P05062; -.
DR   Ensembl; ENST00000374855; ENSP00000363988; ENSG00000136872.
DR   GeneID; 229; -.
DR   KEGG; hsa:229; -.
DR   UCSC; uc004bbk.3; human.
DR   CTD; 229; -.
DR   DisGeNET; 229; -.
DR   GeneCards; ALDOB; -.
DR   H-InvDB; HIX0125611; -.
DR   HGNC; HGNC:417; ALDOB.
DR   HPA; CAB020827; -.
DR   HPA; HPA002198; -.
DR   MalaCards; ALDOB; -.
DR   MIM; 229600; phenotype.
DR   MIM; 612724; gene.
DR   neXtProt; NX_P05062; -.
DR   OpenTargets; ENSG00000136872; -.
DR   Orphanet; 469; Hereditary fructose intolerance.
DR   PharmGKB; PA24710; -.
DR   eggNOG; KOG1557; Eukaryota.
DR   eggNOG; COG3588; LUCA.
DR   GeneTree; ENSGT00390000010235; -.
DR   HOGENOM; HOG000220876; -.
DR   HOVERGEN; HBG002386; -.
DR   InParanoid; P05062; -.
DR   KO; K01623; -.
DR   OMA; ANCQAAQ; -.
DR   OrthoDB; EOG091G0A9T; -.
DR   PhylomeDB; P05062; -.
DR   TreeFam; TF314203; -.
DR   BioCyc; MetaCyc:HS06234-MONOMER; -.
DR   BRENDA; 4.1.2.13; 2681.
DR   Reactome; R-HSA-70171; Glycolysis.
DR   Reactome; R-HSA-70263; Gluconeogenesis.
DR   Reactome; R-HSA-70350; Fructose catabolism.
DR   SABIO-RK; P05062; -.
DR   UniPathway; UPA00109; UER00183.
DR   ChiTaRS; ALDOB; human.
DR   EvolutionaryTrace; P05062; -.
DR   GeneWiki; Aldolase_B; -.
DR   GenomeRNAi; 229; -.
DR   PRO; PR:P05062; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   Bgee; ENSG00000136872; -.
DR   CleanEx; HS_ALDOB; -.
DR   ExpressionAtlas; P05062; baseline and differential.
DR   Genevisible; P05062; HS.
DR   GO; GO:0034451; C:centriolar satellite; IDA:BHF-UCL.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005815; C:microtubule organizing center; IDA:BHF-UCL.
DR   GO; GO:0051117; F:ATPase binding; IDA:BHF-UCL.
DR   GO; GO:0008092; F:cytoskeletal protein binding; IDA:BHF-UCL.
DR   GO; GO:0070061; F:fructose binding; IMP:BHF-UCL.
DR   GO; GO:0061609; F:fructose-1-phosphate aldolase activity; IDA:MGI.
DR   GO; GO:0004332; F:fructose-bisphosphate aldolase activity; IDA:BHF-UCL.
DR   GO; GO:0042802; F:identical protein binding; IPI:BHF-UCL.
DR   GO; GO:0061621; P:canonical glycolysis; TAS:Reactome.
DR   GO; GO:0030388; P:fructose 1,6-bisphosphate metabolic process; IDA:BHF-UCL.
DR   GO; GO:0061624; P:fructose catabolic process to hydroxyacetone phosphate and glyceraldehyde-3-phosphate; TAS:Reactome.
DR   GO; GO:0006000; P:fructose metabolic process; IMP:BHF-UCL.
DR   GO; GO:0006094; P:gluconeogenesis; TAS:Reactome.
DR   GO; GO:0006096; P:glycolytic process; IDA:BHF-UCL.
DR   GO; GO:0006116; P:NADH oxidation; IDA:BHF-UCL.
DR   GO; GO:0032781; P:positive regulation of ATPase activity; IGI:BHF-UCL.
DR   GO; GO:0070072; P:vacuolar proton-transporting V-type ATPase complex assembly; IGI:BHF-UCL.
DR   Gene3D; 3.20.20.70; -; 1.
DR   InterPro; IPR029768; Aldolase_I_AS.
DR   InterPro; IPR013785; Aldolase_TIM.
DR   InterPro; IPR000741; FBA_I.
DR   Pfam; PF00274; Glycolytic; 1.
DR   PROSITE; PS00158; ALDOLASE_CLASS_I; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Complete proteome; Cytoplasm; Cytoskeleton;
KW   Direct protein sequencing; Disease mutation; Glycolysis; Lyase;
KW   Phosphoprotein; Polymorphism; Reference proteome; Schiff base.
FT   INIT_MET      1      1       Removed. {ECO:0000250|UniProtKB:Q91Y97,
FT                                ECO:0000269|PubMed:2649152}.
FT   CHAIN         2    364       Fructose-bisphosphate aldolase B.
FT                                /FTId=PRO_0000216940.
FT   ACT_SITE    188    188       Proton acceptor. {ECO:0000250}.
FT   ACT_SITE    230    230       Schiff-base intermediate with
FT                                dihydroxyacetone-P.
FT   BINDING      56     56       Substrate.
FT   BINDING     147    147       Substrate.
FT   SITE        364    364       Necessary for preference for fructose
FT                                1,6-bisphosphate over fructose 1-
FT                                phosphate.
FT   MOD_RES       2      2       N-acetylalanine.
FT                                {ECO:0000250|UniProtKB:Q91Y97}.
FT   MOD_RES      13     13       N6-succinyllysine.
FT                                {ECO:0000250|UniProtKB:Q91Y97}.
FT   MOD_RES      36     36       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES      39     39       Phosphothreonine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES      89     89       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     119    119       Phosphothreonine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     121    121       N6-succinyllysine.
FT                                {ECO:0000250|UniProtKB:Q91Y97}.
FT   MOD_RES     132    132       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     272    272       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     276    276       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     299    299       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P00884}.
FT   MOD_RES     301    301       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P00884}.
FT   MOD_RES     309    309       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     317    317       N6-succinyllysine.
FT                                {ECO:0000250|UniProtKB:Q91Y97}.
FT   VARIANT      46     46       R -> W (in HFI; reduced enzymatic
FT                                activity; dbSNP:rs41281039).
FT                                {ECO:0000269|PubMed:20848650}.
FT                                /FTId=VAR_075348.
FT   VARIANT      74     74       I -> T (in HFI; affects proper folding;
FT                                dbSNP:rs781023784).
FT                                {ECO:0000269|PubMed:15532022}.
FT                                /FTId=VAR_020822.
FT   VARIANT     120    121       Missing (in HFI).
FT                                {ECO:0000269|PubMed:15532022}.
FT                                /FTId=VAR_020823.
FT   VARIANT     134    134       R -> S (in dbSNP:rs10123355).
FT                                /FTId=VAR_038429.
FT   VARIANT     135    135       C -> R (in HFI; America; partial
FT                                activity). {ECO:0000269|PubMed:8299883}.
FT                                /FTId=VAR_000551.
FT   VARIANT     148    148       W -> R (in one subject with fructose
FT                                intolerance; rare variant; America;
FT                                dbSNP:rs118204430).
FT                                {ECO:0000269|PubMed:7717389}.
FT                                /FTId=VAR_000552.
FT   VARIANT     150    150       A -> P (in HFI; frequent mutation;
FT                                dbSNP:rs1800546).
FT                                {ECO:0000269|PubMed:10024431,
FT                                ECO:0000269|PubMed:12205126,
FT                                ECO:0000269|PubMed:15532022,
FT                                ECO:0000269|PubMed:15880727,
FT                                ECO:0000269|PubMed:20848650,
FT                                ECO:0000269|PubMed:3383242}.
FT                                /FTId=VAR_000553.
FT   VARIANT     175    175       A -> D (in HFI; frequent mutation;
FT                                dbSNP:rs76917243).
FT                                {ECO:0000269|PubMed:10024431,
FT                                ECO:0000269|PubMed:12205126,
FT                                ECO:0000269|PubMed:15532022,
FT                                ECO:0000269|PubMed:15880727,
FT                                ECO:0000269|PubMed:1967768,
FT                                ECO:0000269|PubMed:20848650}.
FT                                /FTId=VAR_000554.
FT   VARIANT     178    178       C -> R (in HFI).
FT                                {ECO:0000269|PubMed:15880727}.
FT                                /FTId=VAR_058211.
FT   VARIANT     185    185       P -> R (in HFI).
FT                                {ECO:0000269|PubMed:12205126}.
FT                                /FTId=VAR_020824.
FT   VARIANT     207    207       E -> Q (in dbSNP:rs3739721).
FT                                /FTId=VAR_020825.
FT   VARIANT     222    222       V -> F (in HFI; affects proper folding).
FT                                {ECO:0000269|PubMed:15532022}.
FT                                /FTId=VAR_020826.
FT   VARIANT     229    229       L -> P (in HFI; affects proper folding).
FT                                {ECO:0000269|PubMed:15532022}.
FT                                /FTId=VAR_020827.
FT   VARIANT     257    257       L -> P (in HFI; Italy;
FT                                dbSNP:rs764701775).
FT                                {ECO:0000269|PubMed:10024431,
FT                                ECO:0000269|PubMed:15532022,
FT                                ECO:0000269|PubMed:8162030}.
FT                                /FTId=VAR_000555.
FT   VARIANT     268    268       I -> N (in dbSNP:rs10989495).
FT                                /FTId=VAR_038430.
FT   VARIANT     284    284       L -> P (in HFI).
FT                                {ECO:0000269|PubMed:15880727}.
FT                                /FTId=VAR_058212.
FT   VARIANT     304    304       R -> Q (in HFI; 100-fold decrease in
FT                                catalytic efficiency for substrates FBP
FT                                and F1P; dbSNP:rs145078268).
FT                                {ECO:0000269|PubMed:10970798}.
FT                                /FTId=VAR_020828.
FT   VARIANT     304    304       R -> W (in HFI; Turkey; 4800-fold
FT                                decrease in catalytic efficiency for FBP
FT                                and inactive with F1P;
FT                                dbSNP:rs555935217).
FT                                {ECO:0000269|PubMed:10024431,
FT                                ECO:0000269|PubMed:10970798}.
FT                                /FTId=VAR_000556.
FT   VARIANT     335    335       N -> K (in HFI; frequent mutation;
FT                                dbSNP:rs78340951).
FT                                {ECO:0000269|PubMed:10024431,
FT                                ECO:0000269|PubMed:12205126,
FT                                ECO:0000269|PubMed:15532022,
FT                                ECO:0000269|PubMed:15880727,
FT                                ECO:0000269|PubMed:2336380}.
FT                                /FTId=VAR_000557.
FT   VARIANT     338    338       A -> V (in HFI; Turkey and South Europe;
FT                                dbSNP:rs77718928).
FT                                {ECO:0000269|PubMed:10024431,
FT                                ECO:0000269|PubMed:15532022}.
FT                                /FTId=VAR_000558.
FT   VARIANT     343    343       Y -> H (in HFI; almost no effect on
FT                                enzymatic activity at 30 degrees Celsius,
FT                                but reduced activity at higher
FT                                temperatures; dbSNP:rs369586696).
FT                                {ECO:0000269|PubMed:20848650}.
FT                                /FTId=VAR_075349.
FT   CONFLICT     54     54       E -> D (in Ref. 5; AAA51691).
FT                                {ECO:0000305}.
FT   CONFLICT    250    250       A -> D (in Ref. 9; CAA25072).
FT                                {ECO:0000305}.
FT   CONFLICT    278    278       E -> D (in Ref. 4; BAA00125).
FT                                {ECO:0000305}.
FT   CONFLICT    309    309       S -> V (in Ref. 3; no nucleotide entry).
FT                                {ECO:0000305}.
FT   CONFLICT    348    348       S -> C (in Ref. 4; BAA00125).
FT                                {ECO:0000305}.
FT   HELIX        10     23       {ECO:0000244|PDB:1QO5}.
FT   TURN         25     27       {ECO:0000244|PDB:1XDL}.
FT   STRAND       29     33       {ECO:0000244|PDB:1QO5}.
FT   HELIX        37     46       {ECO:0000244|PDB:1QO5}.
FT   HELIX        53     64       {ECO:0000244|PDB:1QO5}.
FT   HELIX        68     72       {ECO:0000244|PDB:1QO5}.
FT   STRAND       74     79       {ECO:0000244|PDB:1QO5}.
FT   HELIX        83     85       {ECO:0000244|PDB:1QO5}.
FT   TURN         89     91       {ECO:0000244|PDB:1XDM}.
FT   HELIX        94    100       {ECO:0000244|PDB:1QO5}.
FT   STRAND      104    108       {ECO:0000244|PDB:1QO5}.
FT   STRAND      113    115       {ECO:0000244|PDB:1QO5}.
FT   STRAND      119    121       {ECO:0000244|PDB:1QO5}.
FT   STRAND      123    125       {ECO:0000244|PDB:1QO5}.
FT   HELIX       131    140       {ECO:0000244|PDB:1QO5}.
FT   STRAND      145    152       {ECO:0000244|PDB:1QO5}.
FT   HELIX       161    179       {ECO:0000244|PDB:1QO5}.
FT   TURN        180    182       {ECO:0000244|PDB:1QO5}.
FT   STRAND      184    191       {ECO:0000244|PDB:1QO5}.
FT   HELIX       199    219       {ECO:0000244|PDB:1QO5}.
FT   HELIX       224    226       {ECO:0000244|PDB:1QO5}.
FT   HELIX       246    260       {ECO:0000244|PDB:1QO5}.
FT   STRAND      267    271       {ECO:0000244|PDB:1QO5}.
FT   HELIX       277    289       {ECO:0000244|PDB:1QO5}.
FT   STRAND      290    292       {ECO:0000244|PDB:1XDM}.
FT   STRAND      296    303       {ECO:0000244|PDB:1QO5}.
FT   HELIX       304    306       {ECO:0000244|PDB:1QO5}.
FT   HELIX       308    314       {ECO:0000244|PDB:1QO5}.
FT   HELIX       318    320       {ECO:0000244|PDB:1QO5}.
FT   HELIX       321    338       {ECO:0000244|PDB:1QO5}.
FT   TURN        339    341       {ECO:0000244|PDB:1QO5}.
FT   HELIX       351    354       {ECO:0000244|PDB:1QO5}.
SQ   SEQUENCE   364 AA;  39473 MW;  DCE314E7AC5586CA CRC64;
     MAHRFPALTQ EQKKELSEIA QSIVANGKGI LAADESVGTM GNRLQRIKVE NTEENRRQFR
     EILFSVDSSI NQSIGGVILF HETLYQKDSQ GKLFRNILKE KGIVVGIKLD QGGAPLAGTN
     KETTIQGLDG LSERCAQYKK DGVDFGKWRA VLRIADQCPS SLAIQENANA LARYASICQQ
     NGLVPIVEPE VIPDGDHDLE HCQYVTEKVL AAVYKALNDH HVYLEGTLLK PNMVTAGHAC
     TKKYTPEQVA MATVTALHRT VPAAVPGICF LSGGMSEEDA TLNLNAINLC PLPKPWKLSF
     SYGRALQASA LAAWGGKAAN KEATQEAFMK RAMANCQAAK GQYVHTGSSG AASTQSLFTA
     CYTY
//
